New Treatment Available for IBS-D in Adults

December 14, 2015
Amy Jacob

Global pharmaceutical company Allergan announced today the availability by prescription of Viberzi (eluxadoline), their first-in-class treatment for adult patients suffering from irritable bowel syndrome with diarrhea (IBS-D).

Global pharmaceutical company Allergan announced today the availability by prescription of Viberzi (eluxadoline), their first-in-class treatment for adult patients suffering from irritable bowel syndrome with diarrhea (IBS-D).

Few prescription treatment options that relieve both diarrhea and abdominal pain have been available for IBS-D patients. As such, two clinical trials indicated oral medication Viberzi relieves the primary symptoms of IBS-D — diarrhea and abdominal pain.

Contraindications for Viberzi include:

· Known or suspected biliary duct obstruction, or sphincter of Oddi disease or dysfunction; a history of pancreatitis; structural disease of the pancreas.

· Alcoholism, alcohol abuse, alcohol addiction, or drink more than 3 alcoholic beverages per day.

· Severe hepatic impairment.

· A history of chronic or severe constipation or sequelae from constipation, or known or suspected mechanical gastrointestinal obstruction.

Also, the most commonly reported adverse events during testing were constipation, nausea, and abdominal pain.

William Meury, President and Executive Vice President, Branded Pharma, Allergan, commented, “We are excited about the launch of Viberzi, which addresses an unmet need among IBS-D patients seeking a treatment to manage their symptoms proactively.”